EPJ Web of Conferences
Volume 100, 2015Theoretical and Experimental Studies in Nuclear Applications and Technology (TESNAT 2015)
|Number of page(s)||2|
|Published online||09 July 2015|
Gamma radiation exposure of accompanying persons due to Lu-177 patients
1 Istanbul University, Istanbul Medical Faculty, Nuclear Medicine Department, 34093, Istanbul, Turkey
2 Istanbul University, Science Faculty, Physics Department, 34134, Istanbul, Turkey
3 Süleyman Demirel University, Arts and Sciences Faculty, 32260, Isparta, Turkey
a e-mail : email@example.com
Published online: 9 July 2015
Neuroendocrine tumours (NET) are cancers usually observed and arisen in the stomach, intestine, pancreas and breathing system. Recently, radionuclide therapy applications with Lu-177 peptide compound are rapidly growing; especially effective clinical results are obtained in the treatment of well-differentiated and metastatic NET. In this treatment, Lu-177-DOTA, a beta emitter radioisotope in the radiopharmaceutical form, is given to the patient by intravenous way. Lu-177 has also gamma rays apart from beta rays. Gamma rays have 175 keV average energy and these gamma rays should be under the control in terms of radiation protection. In this study, we measured the exposure dose from the Lu-177 patient.
© Owned by the authors, published by EDP Sciences, 2015
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.